Melatonin Alleviates Acute Kidney Injury by Inhibiting NRF2/Slc7a11 Axis-Mediated Ferroptosis. 2022

Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
Department of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.

Acute kidney injury (AKI) is still a puzzling clinical problem; its pathophysiology is not completely understood. Up to now, an effective treatment for AKI is lacking. Ferroptosis is a novel form of regulated cell death characterized by the lethal accumulation of lipid hydroperoxides that are dependent on iron and reactive oxygen species and mitochondrial dysfunction. Recently, ferroptosis was shown to play a vital role in AKI such as ischemia-reperfusion kidney injury and folic acid-induced AKI. Melatonin (MT) is an antioxidant that regulates the sleep-wake cycle. While the therapeutic effect of melatonin on AKI has been reported, its mechanism for the treatment of renal ferroptosis remains unclear. We found that melatonin treatment significantly alleviated the serum biochemistry index and histopathological alterations in vivo AKI models induced by bilateral renal artery ischemia reperfusion and folic acid in mice. Ferroptosis induced by hypoxia and reoxygenation or erastin (Era) in mouse tubular epithelial cells (MTEC) was also rescued by melatonin treatment. RNA sequence analysis of ferroptosis-related genes showed that melatonin affects oxidative stress responses by inhibiting hypoxia and reoxygenation- (HR-) mediated downregulation of NRF2 and upregulation of Slc7a11 in MTEC. Specific knockdown of NRF2 increased the sensitivity of cells to ferroptosis, and melatonin failed to protect against ferroptosis in the HR condition. Together, our data indicate that melatonin prevents ferroptosis in AKI by acting on the NRF2/Slc7a11 axis.

UI MeSH Term Description Entries
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D005492 Folic Acid A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. Pteroylglutamic Acid,Vitamin M,Folacin,Folate,Folic Acid, (D)-Isomer,Folic Acid, (DL)-Isomer,Folic Acid, Calcium Salt (1:1),Folic Acid, Monopotassium Salt,Folic Acid, Monosodium Salt,Folic Acid, Potassium Salt,Folic Acid, Sodium Salt,Folvite,Vitamin B9,B9, Vitamin
D000079403 Ferroptosis A form of REGULATED CELL DEATH initiated by oxidative perturbations of the intracellular microenvironment that is under constitutive control by glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants. Oxytosis
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D051267 NF-E2-Related Factor 2 A basic-leucine zipper transcription factor that was originally described as a transcriptional regulator controlling expression of the BETA-GLOBIN gene. It may regulate the expression of a wide variety of genes that play a role in protecting cells from oxidative damage. Nfe2l2 Protein,Nuclear Factor (Erythroid-Derived 2)-Like 2 Protein,Nuclear Factor E2-Related Factor 2,NF E2 Related Factor 2,Nuclear Factor E2 Related Factor 2
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D058186 Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions. Acute Kidney Failure,Acute Kidney Insufficiency,Acute Renal Failure,Acute Renal Injury,Acute Renal Insufficiency,Kidney Failure, Acute,Kidney Insufficiency, Acute,Renal Failure, Acute,Renal Insufficiency, Acute,Acute Kidney Failures,Acute Kidney Injuries,Acute Kidney Insufficiencies,Acute Renal Failures,Acute Renal Injuries,Acute Renal Insufficiencies,Kidney Failures, Acute,Kidney Injuries, Acute,Kidney Injury, Acute,Kidney Insufficiencies, Acute,Renal Failures, Acute,Renal Injuries, Acute,Renal Injury, Acute,Renal Insufficiencies, Acute

Related Publications

Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
November 2023, Free radical biology & medicine,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
February 2021, Journal of advanced research,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
January 2023, Drug design, development and therapy,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
September 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
May 2023, Antioxidants (Basel, Switzerland),
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
January 2020, Oxidative medicine and cellular longevity,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
April 2024, Acta pharmacologica Sinica,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
February 2023, International immunopharmacology,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
May 2024, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Yue-Bo Huang, and Ling Jiang, and Xue-Qi Liu, and Xian Wang, and Li Gao, and Han-Xu Zeng, and Wei Zhu, and Xue-Ru Hu, and Yong-Gui Wu
June 2024, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Copied contents to your clipboard!